FM
SLN

Frazier Management’s Silence Therapeutics SLN Stock Holding History

Frazier Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-886,173
Closed -$21.2M – 24
2021
Q4 		$21.2M Buy
+886,173
New +$20.5M 1.63% 22

Other funds holding SLN

LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
LOAME
Lombard Odier Asset Management (Europe) London, United Kingdom $2.37B AUM 28.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Frazier Management's SLN Position: Q1 2022 in Review

Frazier Management sold out of Silence Therapeutics (SLN) in Q1 2022, closing a stake of 886,173 shares — an estimated $21.2M sold.

Frazier Management first reported a position in SLN in Q4 2021 and held it in 1 quarter. The position peaked at $21.2M in Q4 2021. 26 funds tracked by Wall St. Rank hold SLN as of Q1 2022.

  • Frazier Management reported no remaining Silence Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 886,173 Silence Therapeutics shares in Q1 2022, an estimated $21.2M.
  • Frazier Management first reported a position in Silence Therapeutics in Q4 2021 and held it in 1 quarter.
  • Frazier Management's Silence Therapeutics position peaked at $21.2M in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.